Bulletin of Experimental Biology and Medicine

, Volume 157, Issue 3, pp 344–349

Noopept Normalizes Parameters of the Incretin System in Rats with Experimental Diabetes

Authors

    • V. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • N. N. Zolotov
    • V. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • I. V. Ozerova
    • V. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • E. A. Ivanova
    • V. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • I. G. Kapitsa
    • V. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • K. V. Taraban
    • V. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • A. M. Michunskaya
    • V. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • T. A. Voronina
    • V. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • T. A. Gudasheva
    • V. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • S. B. Seredenin
    • V. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
Pharmacology and Toxicology

DOI: 10.1007/s10517-014-2562-5

Cite this article as:
Ostrovskaya, R.U., Zolotov, N.N., Ozerova, I.V. et al. Bull Exp Biol Med (2014) 157: 344. doi:10.1007/s10517-014-2562-5

Experiments on adult Wistar rats with streptozotocin-induced diabetes showed that antihyperglycemic activity of an original nootropic and neuroprotective drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is more pronounced under conditions of oral application than after intraperitoneal injection. These data provided a basis for studying the effect of Noopept on major indexes of the incretin system. Streptozotocin was shown to decrease the concentrations of incretin GLP-1 and insulin in the blood. Noopept had a normalizing effect on these parameters. This influence of Noopept was not related to the inhibition of a major enzyme metabolizing incretins (dipeptidyl peptidase IV). A reference drug sitagliptin also increased the contents of incretins and insulin, which was associated with the inhibition of dipeptidyl peptidase IV. It is known that GLP-1 increases NGF expression in the insular system. Our results suggest that the increase in incretin activity contributes to the antiapoptotic effect of Noopept on pancreatic β cells. The mechanism for an increase in blood GLP-1 level after oral application of Noopept requires further investigations.

Key Words

diabetesNoopeptsitagliptinNGFglucagon-like peptide-1

Copyright information

© Springer Science+Business Media New York 2014